The effect of time and temperature variables on routine coagulation tests

被引:86
作者
Adcock, D
Kressin, D
Marlar, RA
机构
[1] Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA
[2] Denver VA Med Ctr, Lab Serv 113, Denver, CO 80220 USA
[3] Colorado Kaiser Permanente Med Grp, Dept Pathol, Denver, CO USA
关键词
coagulation testing; prothrombin time; activated partial thromboplastin time; stability; temperature; storage variables; NCCLS; ECAT; heparin;
D O I
10.1097/00001721-199809000-00002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study evaluates the effects of time and temperature variables on routine coagulation assays [Prothrombin Time test and Activated Partial Thromboplastin Time (APTT) test]. Four different groups were studied: healthy volunteers, hospitalized patients not receiving anticoagulants, patients receiving oral anticoagulant therapy and patients receiving unfractionated heparin therapy. Samples were subjected to one of four conditions: (1) centrifuged immediately and stored at room temperature (20-22 degrees C); (2) centrifuged immediately and stored on ice (4 degrees C); (3) stored as whole blood without centrifugation, at room temperature and (4) stored without centrifugation, on ice. Coagulation tests were performed as soon as possible after phlebotomy and at specified times up to 24 h. Our data demonstrate that prothrombin time results are stable for up to 24 h, remaining constant regardless of storage conditions. APTT assays are stable for up to 8 h, except for patients receiving unfractionated heparin therapy. Heparinized samples, when stored uncentrifuged at room temperature, demonstrate a clinically significant shortening of the APTT and individual samples demonstrate a greater than 50% decrease in ex-vivo heparin levels at 4 h. Blood Coag Fibrinol 9:463-470 (C) 1998 Lippincott Williams & Wilkins.
引用
收藏
页码:463 / 470
页数:8
相关论文
共 19 条
[1]   MONITORING HEPARIN-THERAPY TO MANAGE THROMBOTIC DISEASE [J].
BICK, RL .
LABORATORY MEDICINE, 1995, 26 (04) :261-265
[2]  
Brigden ML, 1997, AM J CLIN PATHOL, V108, P422
[3]   ESTABLISHING A THERAPEUTIC RANGE FOR HEPARIN-THERAPY [J].
BRILLEDWARDS, P ;
GINSBERG, JS ;
JOHNSTON, M ;
HIRSH, J .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (02) :104-109
[4]   HEPARIN INACTIVATION DURING BLOOD-STORAGE - ITS PREVENTION BY BLOOD COLLECTION IN CITRIC-ACID, THEOPHYLLINE, ADENOSINE, DIPYRIDAMOLE - CTAD MIXTURE [J].
CONTANT, G ;
GOUAULTHEILMANN, M ;
MARTINOLI, JL .
THROMBOSIS RESEARCH, 1983, 31 (02) :365-374
[5]  
DANGELO A, 1991, J INT FED CLIN CHEM, V5, P62
[6]  
EICHOULD A, 1992, MT TODAY, V2, P3
[7]  
HIRSH J, 1995, CHEST, V108, pS259
[8]  
HUSEBY RM, 1978, M J CLIN PATHOL, V69, P99
[9]  
KOEPKE JA, 1975, AM J CLIN PATHOL, V64, P591
[10]  
LANE DA, 1986, J BIOL CHEM, V261, P3980